Nasser Khan

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

Andrea Rubbert‐Roth, Jeffrey Enejosa, Aileen L. Pangan et al. · New England Journal of Medicine · 2020 · 298 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop et al. · Annals of the Rheumatic Diseases · 2020 · 233 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Mark C. Genovese, Josef S Smolen, Michael E. Weinblatt et al. · Arthritis & Rheumatology · 2016 · 201 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Joel M. Kremer, Paul Emery, Heidi S. Camp et al. · Arthritis & Rheumatology · 2016 · 183 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Roy Fleischmann, Eduardo Mysler, Louis Bessette et al. · RMD Open · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17